Novo Nordisk’s Phase 3 failure of IL-6 drug ziltivekimab rattles inflammation-focused pipeline

Novo Nordisk reported that its late-stage IL-6 inhibitor ziltivekimab did not achieve its primary goal in the Phase 3 ZEUS trial, which was designed to lower cardiovascular complications.

The disappointment sent shockwaves through the market, with BioAge Labs and Monte Rosa Therapeutics seeing their shares plunge sharply, while other firms with inflammation‑centric programs also experienced modest declines.

BioAge’s flagship candidate, BGE-102, targets cardiovascular risk through a different mechanism but relies on the same inflammation biomarker, hs‑CRP. The ZEUS miss raises doubts about the broader strategy of targeting inflammation for heart disease.

Analysts suggest the setback may cause companies to reevaluate investments in IL-6 pathways and explore alternative targets for cardiovascular risk reduction.